Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, ...

A ruthenium catalyst facilitated the polymerization, or polymer addition. Industrial firms have used this catalyst to make ...

CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...

Lehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science ...

Scribe Therapeutics, co-founded by Jennifer Doudna, is reducing staff, the latest layoffs among companies focused on CRISPR ...

Bengaluru-based biotechnology startup, CrisprBits Private Limited, has inaugurated a CRISPR gene editing and diagnostics ...

Colossal Biosciences wants to bring back the woolly mammoth and has raised $200 million at a $10.2 billion valuation to do it ...

CRISPR Therapeutics is a mid-stage biotech specializing in gene editing. It became the first gene-editing treatment that uses the Nobel Prize-winning CRISPR technique, an impressive achievement by ...

The scientific team at the laboratory is headed by a group of women with a track record in genomic science, molecular ...

The core components of CRISPR-based genome-editing therapies are bacterial proteins called nucleases that can stimulate ...